Although the most recent Clinical Pharmacogenetics Implementation Consortium (CPIC) publication includes dosing guidelines based on TPMT and NUDT15 metabolizer status22, they mainly apply to AZA treatment in ALL and IBD patients. Here, TPMT is linked to inflammatory bowel disease.